Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, is pleased to announce that Chief Executive Officer Dr. Alastair Smith will be hosting a webinar on Wednesday, 10 April 2024 at 5:30pm (BST).
The webinar will cover the Company’s updated clinical data from the first-in-human Phase 1 trial of AVA6000, the first of the Company’s pre|CISION™ peptide drug conjugates that targets chemotherapy to the tumor, which are to be presented at the 2024 American Association for Cancer Research Annual Meeting, taking place in San Diego, California from 5-10 April 2024. The updated clinical data will be presented in the Phase 1 Clinical Trials 2 Poster Session on 9 April 2024.
There will be a Q&A session for investors after the presentation and questions can be submitted pre-event as part of the registration process.
You can register for the event by using the following link:
https://www.turnerpope.com/register/
We are delighted to announce that the webinar will be chaired by news and corporate events presenter Katie Pilbeam (www.katiepilbeam.com) and hosted by Turner Pope Investments.